University of Basel

Faculty of Medicine

European Center of Pharmaceutical Medicine

CAS/DAS in Pharmaceutical Medicine
MAS in Medicines Development

2025–2027

ECPM®
European Center of Pharmaceutical Medicine

CONTINUING EDUCATION

Table of Contents

Under the auspices of
EUCOR the European Campus
IFAPP, International Federation of Associations of Pharmaceutical Physicians and Pharmaceutical Medicine
Accredited by SwAPP, Swiss Association of Pharmaceutical Professionals and SGPM, Swiss Association of Pharmaceutical Medicine
Recognized as PharmaTrain Centre of Excellence

eucor The European Campus

IFAPP Pharmaceutical Medicine

SwAPP Swiss Association of Pharmaceutical Professionals

sgpm ashmp

Foederatio Pharmaceutica Helvetiae FPH

PharmaTrain MASTERING MEDICINES DEVELOPMENT CENTRE OF EXCELLENCE

Invitation

The European Center of Pharmaceutical Medicine (ECPM) is dedicated to being Europe's leading university institute for medicines and drug development. Established 1991, ECPM was founded to meet the educational needs of specialists in drug development. Affiliated with the department of Public Health of the Medical Faculty at the University of Basel, ECPM collaborates globally and is accredited as an IMI PharmaTrain 'Centre of Excellence'. It is also recognized by the International Federation of Associations of Pharmaceutical Physicians and Pharmaceutical Medicine (IFAPP) and their respective national associations.

We offer a range of training programs designed to provide a comprehensive understanding of the drug, medicines or device development process – from discovery to bedside. Our curriculum is continuously updated to reflect the latest and future trends of scientific developments, thanks to our distinguished international faculty.

Our focus is on Advanced Studies and Continuing Professional Development (CPD). In conformity with the Bologna system, our programs include a Certificate of Advanced Studies (CAS) in Pharmaceutical Medicine, a Diploma of Advanced Studies (DAS) in Pharmaceutical Medicine, and a Master of Advanced Studies (MAS) in Medicines Development. Completing the DAS degree qualifies for specialization recognition by the Swiss Associations of Pharmaceutical Physicians/Professionals (SwAPP/SGPM).

Our programs are tailored for representatives from the pharmaceutical and service industries, academia, and government decision and policy makers who already possess a good understanding of the basics of drug development. Participants will gain an in-depth, comprehensive and systematic immersion into modern medical product and device development, regulation and market introduction.

ECPM training programs offer the flexibility to balance full time work and study, engage with experts, deepen your knowledge, expand your expertise, and build a professional network aligned with your career plan.

An international faculty of experts from academia, pharmaceutical and biotechnology companies, and regulatory authorities carry the teaching responsibility.

We cordially invite you to participate in the ECPM course and very much look forward to meeting you soon!

Prof Thomas D. Szucs
Director

Dr Annette Mollet
Head of Education & Training

Monika Graff
Course Director

Life Long Learning
Deepen your expert knowledge and build an international network

Workplace of students

(2023 – 2025)



Small to Medium Size Pharma	13%
Big Pharma Top 20	55%
CROs, Expert Services	5%
Regulatory Authority	9%
University Hospitals	8%
Academia	2%
Medical Supplies	1%
Freelance	3%
Medical Practice	2%
Consulting	3%
Total	100%

Mission

Our mission is to create the best international training platform that enhances the knowledge, expertise and skills required to perform modern discovery, development, regulation and marketing of medical products. Our outstanding faculty integrates cutting-edge concepts and best practices to enable the development of efficient, economical, high quality and safe medical products for the benefit of the patients and society. We are committed to constant innovation, offering Swiss excellence combined with a global perspective.

Definition of Pharmaceutical Medicine

The International Federation of Associations of Pharmaceutical Physicians and Pharmaceutical Medicine defines Pharmaceutical Medicine as "the scientific discipline for the discovery, development, evaluation, registration, monitoring, and medical marketing of medicines for the benefit of the patients."

Target Audience

Our programs are tailored for representatives from the pharmaceutical and service industries, academia, and government decision and policy makers who already possess a good understanding of the basics of drug development. Participants will benefit from a comprehensive, in-depth exploration of modern medical product and device development, regulation, and market introduction.

Syllabus: IMI PharmaTrain

Training in Pharmaceutical Medicine covers all aspects of pharmaceutical medicine and drug development sciences with an international scope as defined by the PharmaTrain syllabus. This includes the discovery and development of new medicines, biopharmaceutical sciences, clinical pharmacology and trial methodology, good clinical practice and ethics, pharmacovigilance and epidemiology, biostatistics, regulatory affairs, health economics, project and portfolio management, marketing, and new therapeutic approaches.

For details, please see www.pharmatrain.eu/pharmatrain-syllabus or ecpm.ch/education-training/syllabus

Learning Outcomes

On successful completion of training in pharmaceutical medicine, students will be able to demonstrate the following understanding / knowledge:

- The process of drug development and how to incorporate and apply the latest innovative biopharmaceutical development strategies, methodologies and tools
- The principal steps in drug discovery, target identification and non-clinical research
- The pertinent issues involved in the undertaking of clinical research and development
- The regulation of medicines in the various global markets, including ethical and legal provisions
- The management of drug safety issues pre- and post-marketing authorization
- The management of all lifecycle activities (regulatory and marketing) of a medicinal product
- The principles of health economics and their application in the development and marketing of medicinal products

Postgraduate Training

Our postgraduate training offers opportunities to interact with experts in person, build an international network and combine work and continuing education, to transfer knowledge between theory and real world experience. According to the definition of the European Commission, lifelong learning is «all learning activity undertaken throughout life that serves to improve knowledge, skills, and competence».

Following a graduate Bachelor or Master title, three postgraduate titles can be achieved: the first

postgraduate level is the CAS (Certificate of Advanced Studies, 20 ECTS), the second is the DAS (Diploma of Advanced Studies, 30 ECTS) and finally the MAS (Master of Advanced Studies, at least 60 ECTS).

Unique Program Features

- Develop your expertise in the essentials of the medical product lifecycle–from molecule to marketplace–while working full time
- Understand the trends in global pharmaceutical development and health care environment
- Expose yourself to new innovative methods, tools and strategies and apply them in your daily work
- Become a leader and integrator for medical product development
- Create a global professional network and prepare for the next career step
- Enhance your CV by acquiring a Certificate (CAS)/Diploma of Advanced Studies (DAS) in Pharmaceutical Medicine or take it to the next step with a Master of Advanced Studies (MAS) in Medicines Development
- Gain a Swiss specialty recognition for MDs or a SwAPP diploma

University of Basel

The University of Basel is Switzerland's oldest university and has been educating talents since 1460, for instance, the physician and alchemist Paracelsus. Leading higher-education rankings such as the "Academic Ranking of World Universities" consistently place the University of Basel among the world's 100 best universities globally, with its Medical Sciences faculty ranked 75th. Life Sciences are the main focal area at the University of Basel, closely linked with Basel's status as a center of pharmaceuticals and biotechnology.

The ECPM training platform



Postgraduate title system: The first level [L1] represents the Certificate/Diploma of Advanced Studies in Pharmaceutical Medicine including six mandatory basic modules (CAS 20 ECTS/DAS 30 ECTS). The diploma can be supplemented on a second level [L2] with CPD short courses and a thesis to achieve a Master of Advanced Studies [L3] (60 ECTS). The diploma covers also the theoretical part to apply for the Swiss specialist title in pharmaceutical medicine.

Graduates

CAS
since 1991
1292

DAS
since 2001
714

MAS
since 2015
13

Advance your career
by earning a postgraduate title in Pharmaceutical Medicine

Educational background of students

(2023 – 2025)



PhD Pharmacy	5.6%
PhD Engineering	1.9%
PhD Chemistry	5.6%
PhD Biotechnology	15.7%
MD PhD	15.7%
MD	25.9%
MBA	2.8%
MSc Pharmacy	6.5%
MSc Life Science	5.6%
MSc Veterinary	0.9%
MSc Communication	1.9%
MA Economics	0.9%
MA Law	0.9%
MD MSc	5.6%
PharmD	0.9%
BSc Chemistry	1.9%
BSc Biology	1.9%
Total	100.0%

Overview of the Postgraduate Titles

In conformity with the Bologna system, three postgraduate degrees are offered. We believe that in-person interaction provides the best learning experience, which is why we conduct the majority of our diploma courses onsite.

Certificate of Advanced Studies (CAS) in Pharmaceutical Medicine – 20 ECTS
To achieve a Certificate of Advanced Studies (CAS) in Pharmaceutical Medicine by the University of Basel, it is required to successfully complete a two-year course cycle and to pass the multiple choice questions (MCQ) exam.

Diploma of Advanced Studies (DAS) in Pharmaceutical Medicine – 30 ECTS
To achieve a Diploma of Advanced Studies (DAS) in Pharmaceutical Medicine from the University of Basel, participants must successfully complete all the previously mentioned CAS requirements, along with an oral exam and an essay exam. The oral exam involves discussing a peer-reviewed paper that has been assigned for pre-reading. The essay compenent requires writing three one-page summaries on specified topics.

Master of Advanced Studies (MAS) in Medicines Development – 60 ECTS
To earn a Master of Advanced Studies (MAS) in Medicines Development from the University of Basel, participants must fulfill the following requirements:

- successfully complete the DAS (30 ECTS)
- additional selected master modules from the Continuing Professional Development (CPD) short courses program (20 ECTS)
- and write a master thesis (10 ECTS).

Students have the option to enroll in both the ECPM course and the Master concurrently. The total duration of study should not exceed five years.

The additional master modules, relevant to drug development sciences and the IMI PharmaTrain syllabus can be chosen based on preference from ECPM or other course providers/partner universities. It is strongly recommended that students contact the ECPM course directorate to ensure that courses from other universities will be accredited.

The Master thesis topic should ideally relate to the candidates' area of work or special interest. It may be proposed by the participant or developed in consultation with the course directorate. Once the prerequisites are met, the thesis can be started at any time. The final thesis may take the form of a written report not exceeding 40 pages or a manuscript suitable for publication in a scientific journal. It is ideally completed within two semesters.

Swiss Specialist in Pharmaceutical Medicine (FMH and SwAPP)
Participants who successfully complete the DAS can apply for either the Swiss Specialist in Pharmaceutical Medicine Diploma offered by the FMH (Swiss Association of Medical Doctors – www.sgpm.ch) if they are MDs, or the SwAPP (Swiss Association of Pharmaceutical Professionals – www.swapp.ch) Diploma if they hold an MSc or PhD.

Final Examination and Attendance

A minimum attendance of 80% is required to be eligible to to sit the examinations and receive a degree from the University of Basel. The final examination is a closed book test, conducted on iPads onsite on the university campus. Participants pursuing the DAS can choose to take all three exams in one day or spread them over two days. For the FMH title, the exams must be taken on two separate days.

The Bologna Process and the European Higher Education Area

The Bologna Process is a mechanism promoting intergovernmental cooperation between 49 European countries in the field of higher education since 1999. It seeks to bring more coherence to higher education systems across Europe. The system established the European Higher Education Area to facilitate student and staff mobility, and make higher education in Europe more attractive and competitive worldwide.

European Credit Transfer and Accumulation System (ECTS)

The European credit transfer system (ECTS) is a learner-centered system for credit accumulation and transfer, based on the principle of transparency of the learning, teaching, assessment processes and harmonizes the European title system.

	CAS	DAS	Swiss Specialist in PM or SwAPP Diploma	MAS	CPD
6 Diploma Modules	■	■	■	■	□
MCQ Examination	■	■	■	■	□
Oral/Essay Examination	□	■	■	■	□
Single or individual stand alone modules	□	□	□	■	■
Master thesis	□	□	□	■	□
Practical work experience	□	□	■	□	□
ECTS Credits	20	30	30	60	1–5
Results in Title	Certficate of Advanced Studies (CAS) in Pharmaceutical Medicine	Diploma of Advanced Studies (DAS) in Pharmaceutical Medicine	Specialist Title → Application with Professional Association	Master of Advanced Studies (MAS) in Medicines Development	Certificate of Attendance



Biozentrum Basel, entrance hall

Biozentrum Basel, exterior view

ECPM Course and Modules
From Molecule to Marketplace

Course Structure

The ECPM course program consists of

- Six modules of four days each over two years
- 24 face-to-face teaching days plus examination(s)
- Course week: Monday to Thursday
- Case studies: team involvement in mentored breakout sessions
- Approximately eight hours of pre-reading per module
- Course language: English.

1. ECPM Course Modules
The focus of the ECPM course modules is on teaching the fundamentals of drug development.

2. Continuing Education Seminars – 'Frontiers in Drug Development'
During the first three days of each ECPM course module, students focus on learning the fundamentals of drug development. The fourth day is dedicated to a seminar that explores new trends and developments in drug development science.

It is possible to register separately for the 'Frontiers in Drug Development' seminar asa form of continuing professional education. The seminar is open to our alumni and other interested participants.

Diploma Course Cycle 2025–2027

Module 1	Global Drug Development and Pharmaceutical Business Environment	1–4.9 2025
Module 2	From Non-Clinical Testing to First-in-Human	2–5,2. 2026
Module 3	Planning, Collecting and Managing Clinical Data	22–25.6.2026
Module 4	Clinical and Safety Data Evaluation and Biostatistics	7–10.9.2026
Module 5	Global Registration and Approval Process	1–4.2.2027
Module 6	Integrated Product Development, Healthcare Marketplace and Marketing	21–24.6.2027
Final Examination	Multiple Choice	24.8.2027
	Oral / Essay	24.8.2027 and/or 14.9.2027

September 1– 4, 2025

Global Drug Development and Pharmaceutical Business Environment

1

Module 1

Content

The pharmaceutical industry is characterized by long development timelines, high research and development costs, patent protections, and a complex regulatory environment. Companies operate in a global marketplace, navigating different regulatory standards, market needs, and healthcare systems.

Principles and future trends of global pharmaceutical research and development, including implications for drug selection, and regulatory and business evaluations. The role of patenting of new chemical and biological compounds and the innovation in discovery and development as a response to medical and market needs.

Key topics

- Discovering, modifying, assessing and patenting new chemical and biological compounds
- System biology and principles of translational research
- Target identification and validation
- Introduction into the drug development process
- Key stakeholders in the healthcare system
- Design and structure of different healthcare systems
- Project and portfolio management techniques

Learning outcomes

At the end of this module, students should be able to outline the:

1. Principal discovery and validation steps in drug development
2. The elements, functions and management involved in translational research and integrated development of a new drug
3. Principles of patenting new chemical and biological compounds
4. How to balance a pharma portfolio

Martin Traber, MD
President Swiss Society of Pharmaceutical Medicine
Basel, Switzerland

« ECPM is built on the strong foundation of an international syllabus in pharmaceutical medicine. Since its inception, it has helped professionals to see new horizons, including me, and learn what it takes to develop and deliver innovation in the life sciences. I can recommend the course to colleagues at any stage of their professional career to grow their competencies in any healthcare setting »

2

Module 2

February 2–5, 2026

From Non-Clinical Testing to First-in-Human

Content

Methods how to prioritize areas of therapeutic interest and to establish the target product profile. Principles for target identification, understanding of combinatorial chemistry and drugability of new compounds. Exploring possible new drugs through preclinical safety and efficacy testing. The choice and the predictive value of animal testing for toxicity data as well as the principles of ADME, possibilities and opportunities of computer-assisted modeling on the way to proof of concept. Pharmaceutical engineering and choice of formulation.

Key topics

- Non-clinical testing for chemical and biological compounds, including pharmacology (ADME) and toxicology
- Development, testing and formulation of chemical and biological compounds
- Non-clinical testing requirements prior to First-in-Human studies
- Molecular and cellular basis of toxicological reactions
- Genetic and genomic factors in drug development and drug response
- Transition from non-clinical to First-in-Human studies
- Clinical pharmacology and application to clinical development

Learning outcomes

At the end of this module, students should be able to outline the:

1. Value and specifications of non-clinical testing programs and their integration into the overall drug development plan
2. Safety and efficacy considerations
3. Principles of clinical pharmacology and their application to clinical development
4. Impact of genetic predisposition
5. Requirements, planning and regulations of non-clinical and First-in-Human studies

Diane Jorkasky, MD
Expert consultant and board member PA, USA

« Understanding the fundamental principles of drug development independent of disease or indication is critical for anyone who is interested in pursuing a career in the biotech or pharmaceutical medicine. The course is designed specifically with that goal in mind »

June 22–25, 2026

Planning, Collecting and Managing Clinical Data

3

Module 3

Content

The planning, the choice of different trial designs, the randomization modes and the choice of endpoints. The different aspects of the conduct of a trial, i.e. study monitoring, principles of good clinical practice (GCP), adverse event monitoring (risk/benefit assessment) and data management are demonstrated. Basic principles of biostatistics and its application in superiority and non-inferiority trials. Clinical trial registries and data transparency

Key topics

- Early studies in volunteers and patients: dose-finding / proof of concept or mechanism studies
- Confirmatory clinical development plan
- Different types of clinical studies, including superiority and non-inferiority trials
- Planning and managing clinical trials,
- Clinical trial registries
- Legal requirements and Good Clinical Practice (GCP) in the clinical trial process
- Statistical considerations in the design of clinical trial protocols and analysis of clinical trial data
- Patient involvement

Learning outcomes

At the end of this module, students should be able to outline the:

1. Management of early studies in patients and their impact on the drug development plan
2. Principles and practical relevance of ethical and legal issues in biomedical research
3. Design of various types of clinical studies and statistical methods used
4. The confirmatory clinical development plan including the role of relevant study committees
5. Key issues involved in the conduct of a clinical trial study. The role of clinical trial registries

Daniel Buchta, MA
Head of Investor Relations, Lonza
Basel Switzerland

« Coming from the finance industry, I wanted to expand my career opportunities and learn something new. The DAS program provided me with a great overview of the relevant steps in drug development and has embedded everything in the overarching topic. The lecturers came from academia and relevant industry fields. Working full-time, it was manageable to combine studying in parallel »

4

Module 4

September 7–10, 2026

Clinical and Safety Data Evaluation and Biostatistics

Content

Advanced methods of biostatistics and application of different trial designs, within-trial decisions, data management, extraction, manipulation and storage of data. Clinical trial protocol design and final report. Procedures and databases for pharmacovigilance and pharmacoepidemiology surveillance, risk management plans.

Key topics

- Development of a clinical trial protocol and the investigator drug brochure (IDB)
- Legal and ethical provisions for protection of clinical trial subjects
- Statistical methods used in clinical research
- Evaluation and interpretation of clinical trial results
- Introduction to Pharmacovigilance and Pharmaco-Epidemiology
- Collection and evaluation of adverse event data in clinical trials, drug safety monitoring board

Learning outcomes

At the end of this module, students should be able to outline the:

1. Development of a clinical trial protocol and the role of the investigator drug brochure (IDB)
2. Evaluation and interpretation of clinical trial results
3. Main statistical methods used in clinical data analysis
4. Collection and evaluation of adverse event data in clinical trials
5. Pharmacovigilance and risk management concepts

Rossana Rocco
Head of Clinical Programs, Chiesi Farmaceutici SpA
Parma, Italy

« The main assets to this course are its expert faculty, interactive learning environment and practical examples bridging theory to everyday practice. Participants come from different backgrounds providing excellent networking opportunities. I highly recommend this course to those that aim to consolidate and deepen their expertise to leave their own mark in this field »

February 1–4, 2027

Global Registration and Approval Process

5

Module 5

Content

Overview of mechanisms and regulatory management systems in Europe, the USA and other representative countries. Requirements of a regulatory application, documentation and collaboration between developers and regulators. Special regulatory procedures for rare diseases and vulnerable populations, regulatory strategies and crisis management. Product information regulation and summary of product characteristics. Medical devices and combination products.

Key topics

- Regulation of pre- and post-approval of medicines at EU and global level
- Regulatory activities and strategy within a pharmaceutical company
- Summary of product characteristics and labelling requirements
- National and international bodies responsible for medicines regulation and their procedures
- Off-label/unlicensed use of medicines
- International Council for Harmonisation (ICH)
- Preparation and submission of marketing application, common technical document (CTD)
- Communication with regulatory authorities

Learning outcomes

At the end of this module, students should be able to outline the:

1. General principles of medicines and medical devices regulation (both pre- and post-approval)
2. The procedures of the most important regulatory authorities worldwide
3. Preparing necessary documents for drug registration/marketing authorization
4. Regulatory proceduresand strategies for rare diseases and vulnerable populations

Alexandra Kundert, MD Medical Advisor Oncology, Pfizer FMH Candidate Zurich, Switzerland

« As a participant in the ECPM program working towards my specialist title, I am impressed by the exceptional teaching program and the thorough dissemination of knowledge on drug development. The high-quality speakers, evolving curriculum, and diverse networking opportunities have been invaluable, greatly enhancing my career prospects and expanding my expertise in the field »

6

Module 6

June 21–24, 2027

Integrated Product Life, Healthcare Marketplace and Marketing

Content

Principles of project and portfolio management, including aspects of planning, project valuation and decision making. How to successfully place a new drug on the market. Principles of Health Economics, market access, health technology assessment and reimbursement strategies. Life cycle management. Mergers and acquisitions.

Key topics

- Principles and regulations of drug marketing
- Good Promotional Practice: ethical and legal principles pertaining to marketing activities
- Health economics and health technology assessment (HTA)
- Life cycle management
- Strategic considerations of portfolio management
- Mergers and Acquisitions

Learning outcomes

At the end of this module, students should be able to outline the:

1. Drug lifecycle activities and management
2. Market access and introduction of a drug
3. Principles and practical application of health economics, health technology assessment (HTA), pricing and reimbursement
4. Value of mergers and acquisitions

Djordje Filipovic, Ph.D., CEO AB2 Bio Ltd., Lausanne Switzerland

« ECPM lays the foundation for contributing cross-functionally and is therefore a steppingstone to future Team Leadership and General Management positions. In all the years I was privileged to lecture, I always benefitted from the sizzling diversity of participants making every discussion a mutually beneficial reverse mentoring experience »

Art work at Biozentrum representing the Pharmahub Basel

Teaching Framework
Combine onsite training with the online learning platform

Teaching Principle

The ECPM course follows the IMI PharmaTrain Syllabus for postgraduate education in Pharmaceutical Medicine and aims for the highest academic standard based on Bloom's Taxonomy of Educational Objectives. The learning process includes didactic teaching and places a great emphasis on interactive participation. Each module includes the following activities:

Lectures
Selected faculty from industry, academia and regulatory authorities provide state-of-the-art lectures spanning both the basics of drug development as well as current trends in important drug, diagnostic and therapeutic areas as well as related issues.

Lectures focus on interactive learning, in-depth discussions and break-out groups, where participants work on case studies that complement the lectures in each module. To ensure that the curriculum is aligned with trends in pharmaceutical medicine, ECPM continuously consults with an advisory board of external specialists.

The course language is English.

Case Studies
Participants work in small interdisciplinary teams on real-life cases. They analyze and discuss problems with faculty members and develop strategies that they then present and defend in a roundtable discussion. Documents and background literature of the case studies are provided prior to each course module. Students are expected to read these materials in advance to facilitate active participation in the discussion.

Gray Book
A notable feature of the course is the online availability of "Gray's Medicines Development" authored by Dr Julian Gray. This book summarizes key aspects of the PharmaTrain syllabus covering the entire drug development process. A print version is also available for our students to purchase.

Frontiers in Drug Development Seminars
The Frontiers in Drug Development Seminars take place on day four of each course module. They are an integral and mandatory part of the course.

Teaching Evaluation

The University of Basel uses an evaluation software that anonymizes student feedback. This input is highly valued as it helps us maintain high-quality education and identify areas for improvement.

Course Material

All students receive electronic access to the teaching materials a few days before each ECPM course module via our Learning Platform. Printed course binders, containing all course documents, are available for an additional fee of CHF 500 and are delivered on the first day of each module.

Access to the online version of the Gray Book is provided through the Learning Platform, with a print version available for CHF 150.

Participants

The majority of our students have a higher degree, such as an MSc, MD, PhD, PharmD etc. and between three to five years of relevant work experience gained in the pharmaceutical and biotech industries or service industry (e.g. consultancy, CROs), in clinical research or while working for governmental policymakers in integrated medical product development, regulation and market introduction fields.

Participants of the ECPM course represent many different countries and working places worldwide. This variety of backgrounds offers a great opportunity to network and learn from your peers.

Venue of the ECPM course - main auditorium of the Biozentrum, University of Basel.

About ECPM

The leading university institute for Pharmaceutical Medicine for over 30 years

Teaching Faculty



Big Pharma	31%
Small and Medium Sized Enterprises	9%
CRO	7%
Regulatory Authorities	20%
Academia/ University Hospitals	23%
Consultants	9%
Total	100%

About ECPM

The European Center of Pharmaceutical Medicine (ECPM) or Institute of Pharmaceutical Medicine is dedicated to being the leading university institute for medicines and drug development in Europe. ECPM belongs to the department of Public Health of the Medical Faculty at the University of Basel and operates with partners worldwide. The institute was founded in 1991 to cover the training needs of specialists working in drug development. It comprises an education and training department (est. 1991) and a research department (est. 2003). The ECPM course was established in partnership with EUCOR, the European Confederation of the Upper Rhine Universities Medical Schools of the Universities of Basel, Freiburg i. Br. and Strasbourg, together with the pharmaceutical industry. The professorship in Pharmaceutical Medicine was inaugurated in 2009.

International Network

Between 2009 and 2014, ECPM managed a project under the public-private partnership of the Innovative Medicines Initiative (IMI), focused on education and training in medicines development. The project's achievements include a shared training syllabus, shared examination standards, and mutual recognition of learning outcomes and credit points (see www.pharmatrain.eu).

ECPM established an international network and collaboration with courses in drug development and regulatory sciences. Partner courses at the Peking University Research Institute and the University of San Francisco Hub in Washington DC share the same teaching principles and quality label. This unique global collaboration offers the possibility to transfer between the sister courses in Basel, Beijing or Washington DC.

Teaching Faculty

ECPM's teaching faculty consists of over 150 international experts in regulatory sciences, medical product discovery and development, product evaluation and business practices. Lecturers and tutors will be drawn from academia, regulatory agencies (such as EMA, FDA and local agencies), pharmaceutical, diagnostic and biotechnology industry, coverage and reimbursement entities, professional societies and national institutes.

Advisory Board

ECPM's advisory board comprises key stakeholders in medicines development from academia, the pharmaceutical industry, regulatory authorities, the ECPM teaching faculty, EUCOR medical schools and other partner universities. This board serve as a critical sounding board and think tank, reviewing results annually and advising on strategies to keep ECPM's training and research aligned with the latest trends and developments and customer and market needs.

Join us on LinkedIn:

Administrative Information
Welcome to the PharmaHub of Basel!

Tuition Fees CAS/DAS/FMH

- Full course: CHF 15'750.
- Reduced fee: CHF 14'750 (SGPM/ SwAPP continuing training centers "Weiterbildungsstätten" and companieswith 10+ participants)
- Non-profit organizations: on request

The tuition fee includes access to the online Learning Platform ,the Gray Book (online version), lunches, coffee breaks, one networking event per module, and the multiple choice questions (MCQ) exam fee.

Additional Costs:

- Printed course materials (6 binders, 1 per module): CHF 500
- Print version of the Gray Book: CHF 150
- Oral/essay examination (Diploma of Advanced Studies): CHF 750 (non-refundable)

Tuition, or the first installment, is due upon confirmation of attendance, at the latest by June 30, 2025

Payment can be made in two installments (June 30, 2025, and June 30, 2026).

Tuition Fees MAS

- ECPM Course (6 modules; 30 ECTS): CHF 15,750 or applicable reduced fee
- Master Modules (20 ECTS): Fees depend on course provider
- Master Thesis, Final Exam, and Master Diploma (10 ECTS): CHF 3,500

You may register for the Master's degree at any time after starting the ECPM course, with a maximum study duration of five years

	CAS	DAS	Swiss Specialist in PM or SwAPP Diploma	MAS	CPD
6 Diploma Modules	15'750	15'750	15'750	15'750	
Groups and training centres	14'750	14'750	14'750	14'750	
Printed course material (Optional)	500	500	500	500	
Gray book	150	150	150	150	
MCQ Examination **Retake**	– 500	– 500	– 500	– 500	
Oral/Essay Examination **Retake**	na	750 750	750 750	750 750	
Single or individual stand alone modules	na	na	na	750 – 3000 course dependent	750 – 3000
Master thesis				3'500	
Total	15'750	16'500	16'500 plus registration with professional association	about 25'500 depending on choice of modules	na

Tuition fees in CHF / Prices 2024 (can be subject to change)

Nationalities of students

25

Number of students

(1991–2023)

2232

Apply for your postgraduate degree in Pharmaceutical Medicine

Noah Murer
Course Coordinator

Admission Criteria

To enroll in the ECPM course, applicants must hold a higher university degree such as a Master's, MD, PharmD or PhD. This postgraduate program is designed for professionals in the pharmaceutical industry, regulatory agencies, and academia who seek to enhance their expertise. Ideal candidates will have a primary interest in medical product discovery, development, regulation and healthcare systems. Candidates should also have at least one to two years of relevant work experience in the drug development process.
Applications that do not meet these criteria are considered on an individual basis.

Application Dossier

To apply please submit the following via the registration link on the ECPM website:

- A one to two-page curriculum vitae
- A copy of your university diploma (or a certified English or German translation)

Applications are reviewed by the course directorate on an ongoing basis. As enrollment is limited, early application is encouraged.

A strong command of English (C1 level) is required to effectively engage with course material. While formal language certificates are not required, applicants must ensure they possess the necessary proficiency for lectures, discussions, and written assignments.

Registration

Please register online at ecpm.unibas.ch/CAS or ecpm.unibas.ch/DAS for the ECPM course.

For the Master of Advanced Studies, please register at ecpm.unibas.ch/MAS.

If you have questions regarding your registration, please do not hesitate to contact Nicola Liversidge at ecpm@unibas.ch

Deadline for Registration

The next ECPM course cycle begins in September 2025 and concludes in June 2027. The registration deadline is June 30, 2025.
If places are still available, applications may be accepted after the deadline has passed.

Registration as Student of the University of Basel

Participants enrolling in the Certificate of Advanced Studies (CAS) will not be registered as students at the University of Basel. However, those enrolling in the Diploma of Advanced Studies (DAS) or Master of Advanced Studies (MAS) will be registered as students. A separate form for the student card will be provided by the university, and student registration is included in the tuition fee.

Cancellation Policy

- Cancellations made at least four weeks before the course start date (by August 4, 2025) will receive a 100% refund.
- Cancellations made in writing within four weeks of the start date (after August 4, 2025) will incur a CHF 750 administrative fee.
- Cancellation requests made after the course begins will not receive a refund.
- Participants who do not attend on the scheduled dates will be invoiced for the full course fee.

Course Venue

The course will take place on the campus of the University of Basel.

Travel and Accommodation

Participants should book their own travel arrangements and hotel rooms.

Coffee break and networking

Participants of the 17th ECPM Course Cycle (2023–2025).

Imprint

Published by
ECPM
Institute of
Pharmaceutical Medicine
Klingelbergstrasse 61
4056 Basel
Switzerland
www.ecpm.ch

Photography:
Page 3:
© Ursula Sprecher, Basel
Page 8, 17, 19, 23:
© Samuel Bosshardt, Basel
Page 9:
@ Atelier Fontana, Basel
Page 11, 12, 13, 14, 15, 16:
shutterstock

Design Concept and Layout:
atelier w, Basel

Educating
Talents
since 1460.

University of Basel
ECPM
Institute of Pharmaceutical Medicine
Klingelbergstrasse 61
4056 Basel
Switzerland

www.ecpm.ch